GIVE MISS CALL ON :- +91 99774 99927

Category Archives: Top Corporate News

MONETARY POLICY – RBI POLICY OUTCOME

As expected there was no any change in repo rate, it remain constant at 6%. Bench members of six people out of which five were in favor of keeping rates unchanged and one member wanted a rate cut of 25 basis but as per majority MPC decided to keep rates unchanged. In his conversation after

CAPITALSTARS – TOP CORPORATE NEWS – 06 DEC 2017

Dalmia Bharat to bid for debt laded Binani Cement with Piramal Bain fund Dalmia Bharat Cement has entered into an agreement with Piramal Bain Resurgence fund to bid for debt-laden Binani Cement Ltd, as per media sources. Piramal Bain Resurgence fund is an Ajay Piramal and American private equity fund, Bain Capital Credit, venture. Binani

CAPITALSTARS – RBI MONETARY POLICY 06 DEC 2017

RBI monetary policy What to note in RBI monetary policy beyond rate action RBI’s monetary policy committee is likely to leave rates unchanged on Wednesday. Here are three things to watch out for in the policy beyond the rate action. The Reserve Bank of India’s monetary policy committee (MPC) is likely to leave rates unchanged

CAPITALSTARS – Stocks to look out for today: 06 DEC 2017

During the previous trading session, after opening gap and testing its 100-SMA, Nifty rebounded to close flat with negative bias. The price action has resulted in the formation of doji candle which indicates indecision. Going forward, a follow through correction below the 100-SMA, which is placed around 10,070, may see the Nifty extending its correction

CAPITALSTARS – Market Outlook for the coming week!

Market Outlook for the coming week! The RBI’s monetary policy committee (MPC) will meet on December 06, 2017. In the primary market, Shalby, which runs a multi-speciality hospital chain, will open its initial public offering ( IPO) on December 05, 2017. Shalby has set a price band of Rs245-248 per share for the IPO. The

CAPITALSTARS – TOP CORPORATE NEWS – 01 DEC 2017

Biocon gets EU regulator nod for trastuzumab biosimilar Mylan N.V. and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Applicat- ions (MAA) for proposed biosimilar trastuzumab and proposed biosimilar pegfilgrastim. EMA acceptance of the submissions follows an earlier withdrawal of both applications in response to an audit conducted

Checking...

Ouch! There was a server error.
Retry »

Sending message...

FREE TRIAL REQUEST


CapitalStars FORUM